Evaluation of Limb-Girdle Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00893334
Recruitment Status : Completed
First Posted : May 6, 2009
Last Update Posted : March 7, 2014
Carolinas Medical Center lead study site
Information provided by (Responsible Party):
Cooperative International Neuromuscular Research Group

May 4, 2009
May 6, 2009
March 7, 2014
April 2009
December 2013   (Final data collection date for primary outcome measure)
  • The measurement of growth factors (TGF-B, IGF-II) and cytokines (IL18, IL1A, and IL1B) between the different types of LGMD and BMD. [ Time Frame: 12 months ]
  • The difference in the growth factors (TGF-B, IGF-II) and cytokines (IL18, IL1A, and IL1B) pre-evaluation and post-evaluation. [ Time Frame: 12 months ]
Same as current
Complete list of historical versions of study NCT00893334 on Archive Site
  • Evaluation of surrogate and clinically relevant outcome measures in LGMD. [ Time Frame: 24 months ]
  • Quality of life questionnaires to correlate patient- perceived limitations in daily activities with the quantitative strength measurements and functional ability with timed testing. [ Time Frame: 24 months ]
  • Evaluation of patient understanding in their diagnosis and genetic etiology of their diagnosis. [ Time Frame: 24 months ]
Same as current
Not Provided
Not Provided
Evaluation of Limb-Girdle Muscular Dystrophy
Evaluation of Limb-Girdle Muscular Dystrophy
The purpose of this study is to understand the biochemistry of different types of Limb-Girdle Muscular Dystrophy (LGMD) and to determine appropriate outcome measures for future clinical treatment trials for LGMD. It is being conducted at two sites in the Cooperative International Neuromuscular Research Group (CINRG). It involves a one day clinical evaluation at a participating institution that will take approximately four to six hours, and will involve strength testing and muscle functional testing by a physical therapist, an evaluation by a physician, pulmonary function testing, a complete cardiac evaluation with electrocardiogram (ECG or EKG) and echocardiogram (Echo), and involve two blood draws, one before the evaluation and one after the evaluation is complete. During the visit, the participant will be asked to fill out a couple of questionnaires asking questions about quality of life and activity limitations, as well as his/her understanding of their diagnosis with regards to etiology (or cause of their muscle disorder), genetics, and inheritance of their muscle disorder.

Specific Aims:

Aim 1: Evaluate integrity of the extracellular matrix in patients with LGMD by measuring serum growth factors and cytokines and compare these to a disease control (BMD) and normal volunteers.

Aim 2: Measure growth factors and cytokines following medical evaluation and compare them to the baseline levels.

Aim 3: Discovery Aim for future multicenter clinical trials in LGMD. Aim 3A: Abstract medical records with particular emphasis on age of disease onset, initial clinical symptoms, progression and location of the muscular weakness, treatments attempted, and other medical complications. A review of the diagnostic testing performed will also be conducted.

Aim 3B: Perform complete clinical evaluation including anthropometric measures, evaluation of joint limitations, timed functional testing, muscle strength, pulmonary function, and a cardiac assessment.

Aim 3C: Determine patient understanding of diagnosis of LGMD and genetic testing results. A questionnaire will be generated that addresses the patient's understanding of his/her diagnosis as well as their understanding of genetic concepts of autosomal recessive inheritance, genes, molecular testing and implications for themselves as well as their family.

Aim 3D: Quality of Life (QOL) questionnaires will be administered. These will be used to identify functional limitations by the patients and compare those limitations with the clinical evaluation.

Study Description

Only one visit will be necessary for this study. The study visit includes:

  1. Review of the informed consent form
  2. Blood collection Blood will be collected for the following: DNA extraction to confirm genotype if not already performed; Muscle Enzymes before and after physical evaluation; and Growth factors and cytokines: before and after physical evaluation.
  3. Medical history review
  4. Physical Examination
  5. Questionnaires: Participants will complete 3 questionnaires: Diagnosis and genetic testing, ACTIVLIM, and INQoL
  6. Clinical Evaluator assessment which includes: Manual Muscle Testing, Quantitative Muscle Testing, Pulmonary Function Testing, Anthropometric measurements, and Timed and Functional testing
  7. Cardiac evaluation will include: Electrocardiogram and Echocardiogram

Control subjects will be required to come to the test site to complete the informed consent process, clinical evaluator assessment, and have blood drawn before and after the clinical evaluator assessment. No other examinations or procedures will be performed on the control participants.

Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Blood samples will be collected one time for DNA analysis.Only to confirm genotype if results are not available prior enrollement
Non-Probability Sample
The subject population will include all patients diagnosed LGMD2I, LGMD2A, LGMD2B, and BMD. BMD is an X-linked recessive condition that only affects males. It has been described in all ethnic backgrounds. LGMD2I, LGMD2A and LGMD2B are autosomal recessive conditions affecting both males and females of all ethnic backgrounds equally, both sexes and all ethnicities are expected to be equally represented. Clinical symptoms manifest in the second decade of life, therefore all participants will be over the age of 18. Healthy controls will be recruited to match the study population based on age, sex, and ethnicity.
  • Becker Muscular Dystrophy
  • Limb-Girdle Muscular Dystrophy, Type 2A (Calpain-3 Deficiency)
  • Limb-Girdle Muscular Dystrophy, Type 2B (Miyoshi Myopathy, Dysferlin Deficiency)
  • Limb-Girdle Muscular Dystrophy, Type 2I (FKRP-deficiency)
Not Provided
  • BMD:
    Patients diagnosed with Becker Muscular Dystrophy
  • LGMD2A
    patient diagnosed with Limb-Girdle Muscular Dystrophy, type 2A Calpain-3 deficiency
  • LGMD2B
    Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2B Miyoshi myopathy Dysferlin deficiency
  • LGMD2I
    Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2I FKRP-deficiency
  • Control
    Healthy Controls
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2013
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years of age or older.
  • Diagnosis of LGMD2I, LGMD2A, LGMD2B, or BMD as determined by muscle biopsy immunohistochemistry, immunoblotting, or molecular analysis.
  • Able to travel to study site
  • Normal controls will be recruited as either friends of the study participants or through separate recruitment.

Exclusion Criteria:

  • Unable to travel to study site.
  • Do not have the diagnosis of LGMD2I, LGMD2A, LGMD2B, or BMD after review of clinical testing.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
MDA Grant: 129066
Not Provided
Not Provided
Cooperative International Neuromuscular Research Group
Cooperative International Neuromuscular Research Group
Carolinas Medical Center lead study site
Principal Investigator: Carolina Tesi-Rocha, M.D. Cooperative International Neuromuscular Research Group
Principal Investigator: Susan Sparks, M.D., Ph.D. Levine Children's Hospital at Carolinas Medical Center
Cooperative International Neuromuscular Research Group
March 2014